Review



anti human leukemia inhibitory factor lif antibodies  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems anti human leukemia inhibitory factor lif antibodies
    Anti Human Leukemia Inhibitory Factor Lif Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/Human+LIF+Antibody/pm39855425-94-18-26
    Average 93 stars, based on 21 article reviews
    anti human leukemia inhibitory factor lif antibodies - by Bioz Stars, 2026-09
    93/100 stars

    Images



    Similar Products

    93
    R&D Systems anti human leukemia inhibitory factor lif antibodies
    Anti Human Leukemia Inhibitory Factor Lif Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/Human+LIF+Antibody/pm39855425-94-18-26
    Average 93 stars, based on 1 article reviews
    anti human leukemia inhibitory factor lif antibodies - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec leukemia inhibitory factor
    Leukemia Inhibitory Factor, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/LIF+Antibody%2C+anti-human%2C+REAfinity/pm34782763-236-31-35
    Average 94 stars, based on 1 article reviews
    leukemia inhibitory factor - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    90
    R&D Systems anti-human leukemia inhibitory factor (lif) antibody (goat polyclonal igg, p15018)
    Anti Human Leukemia Inhibitory Factor (Lif) Antibody (Goat Polyclonal Igg, P15018), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/anti+human+lif+antibody++goat+polyclonal+igg++p15018++for+neutralization+assay/pm29577936-42-0-16
    Average 90 stars, based on 1 article reviews
    anti-human leukemia inhibitory factor (lif) antibody (goat polyclonal igg, p15018) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    R&D Systems human leukemia inhibitory factor lif blocking antibody
    Cytokines/growth factors released into the conditioned medium of hAFSCs and MSCs and effects on tubular cell proliferation. A: Evaluation of cytokines/growth factors released into the conditioned medium of 1 × 106 hAFSCs and MSCs after a 12-hour incubation in RPMI 1640 plus 0.5% bovine serum albumin. Cytokines were measured using a multiplex cytokine array. Data represent the mean ± SD of five different cell lines. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; <t>LIF,</t> leukemia <t>inhibitory</t> factor; NGF, nerve growth factor; SCF, stem cell factor; SDF, stromal derived factor; HGF, hepatocyte growth factor. B: Proliferation of TECs induced by the conditioned medium (CM) of hAFSCs and MSCs was evaluated by incorporation of BrdU and expressed as the percent increase over unstimulated control cells (Ctrl). The role of LIF in proliferation induced by the conditioned medium was evaluated using 3 μg/ml anti-LIF blocking antibodies (Ab-LIF). Data represent the mean ± SD of three different experiments performed in duplicate. Analysis of variance with Dunnett's comparison test: *P < 0.005, CM plus Ab-LIF versus CM alone.
    Human Leukemia Inhibitory Factor Lif Blocking Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/Human+LIF+Antibody/pmc02947295-77-29-36
    Average 93 stars, based on 1 article reviews
    human leukemia inhibitory factor lif blocking antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology goat anti-human leukemia inhibitory factor lif polyclonal antibody
    Cytokines/growth factors released into the conditioned medium of hAFSCs and MSCs and effects on tubular cell proliferation. A: Evaluation of cytokines/growth factors released into the conditioned medium of 1 × 106 hAFSCs and MSCs after a 12-hour incubation in RPMI 1640 plus 0.5% bovine serum albumin. Cytokines were measured using a multiplex cytokine array. Data represent the mean ± SD of five different cell lines. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; <t>LIF,</t> leukemia <t>inhibitory</t> factor; NGF, nerve growth factor; SCF, stem cell factor; SDF, stromal derived factor; HGF, hepatocyte growth factor. B: Proliferation of TECs induced by the conditioned medium (CM) of hAFSCs and MSCs was evaluated by incorporation of BrdU and expressed as the percent increase over unstimulated control cells (Ctrl). The role of LIF in proliferation induced by the conditioned medium was evaluated using 3 μg/ml anti-LIF blocking antibodies (Ab-LIF). Data represent the mean ± SD of three different experiments performed in duplicate. Analysis of variance with Dunnett's comparison test: *P < 0.005, CM plus Ab-LIF versus CM alone.
    Goat Anti Human Leukemia Inhibitory Factor Lif Polyclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/goat+polyclonal+anti+lif+antibody/pm15537866-72-48-56
    Average 90 stars, based on 1 article reviews
    goat anti-human leukemia inhibitory factor lif polyclonal antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    R&D Systems human leukemia inhibitory factor soluble receptor α
    Figure 1. Comparison of yield and immunoreactivity of proteins from chorionic villous samples extracted and solubilized with different reagents. (A) Glycogen, at a high pH, and sarkosyl (SK) increased the solubility of proteins in TRIZOL protein pellets from villous tissue (39-week pregnancy). Protein pellets, precipitated from TRIZOL supernatants in the absence of glycogen, were extracted with 50 mM Tris-Cl buffer at the pH indicated from the equivalent of 2.5 mg tis- sue (lanes 2–9), from 1–10 mg tissue precipitated in the presence of glycogen (lanes 11–14; in lane 11, 2.5 mg tissue equivalent were loaded and, in lane 12, 2 mg tissue equivalent were loaded), and from 2 mg tissue with or without sarkosyl at pH 6.8 (lanes 16 and 17) and at pH 8.8 (lanes 18 and 19). Protein concentrations from six different experiments were measured, and the mean (x– ± SEM) relative increase in recovery at pH 7.5, 8.0, and 8.8, compared to that at pH 6.8, are shown (lanes 2–9). Patient samples were villous tissues from two 39-week (39- and 38.4-week, caesarean delivery), two 12-week (12- and 12.1-week, voluntary termi- nation of pregnancy) pregnancies, and fetal brain (13.1-week with Down syndrome). (B) Lanes 2–5, proteins were directly extracted from 50 mg villous tissue (39-week pregnancy) at pH 8.0, tissue protein extraction reagent (T-PER), and from TRIZOL pellets (lanes 6 and 7). (C) Villous proteins (38.4-week pregnancy) extracted directly (lanes 1–4) at conditions indicated were resolved in 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels, electrotransferred to Immobilon polyvinylidene difluoride (PVDF) membrane, immunostained [upper panel; antibody (Ab)] with affinity-purified polyclonal goat anti-human interferon γ recep- tor (IFNGR) 2, and membranes were then stained with 0.25% Coomassie blue (lower panel; stain). (D) Similar experiment to panel A (lanes 2–9), except that vil- lous tissue was from a 12-week pregnancy and the proteins transferred to a PVDF membrane were first immunoreacted with anti-human IFNGR 2 antibody, and, subsequently, the membrane was stripped and reprobed with β-actin antibody. Fold increase in staining at different pHs compared to that at pH 6.8 is shown below the bands; lanes 9 and 10, proteins were extracted at pH 8.8, and fold-increase by glycogen is shown for IFNGR 2 and β-actin. (E) Similar experiment (villous tissue from a 12.1-week pregnancy) to panel D, except it was first immunostained with anti-human leukemia <t>inhibitory</t> factor-soluble <t>receptor</t> <t>α</t> <t>(LIF-sRα)</t> and subsequently with β-actin. (F) Villous proteins (38.4-week pregnancy) were extracted at pH 6.8 (lanes 1 and 2), pH 8.0 (lanes 3 and 4), and pH 8.8 (lanes 5 and 6) in the presence and absence of sarkosyl. (G) RNA analysis from samples used for protein extraction; lanes 1 and 2, 5 µg total RNA from experiments shown in panels A–C and F (two 39-week villous tissue) were resolved on agarose gel, which demonstrated the quality of 28S and 18S ribosomal RNAs; the cDNA pre- pared from 12-week (Figure 1D) and 39-week pregnancies (A) were used to amplify IFNGR1 (forward, 5′-GAATGAACGGAAGTGAGATCCA-3′ and reverse, 5′-CCTGGAACTGTTGCTGGAGA-3′), 8.0 (forward, 5′-TCAGGGATAGCCCCCATCTAT-3′ and reverse, 5′-AACCCTTTGCCACTACATCAATTT-3′), and 3.1 kb (forward, 5′-CCGCTGAAAGAGGGGGAA-3′ and reverse, 5′-TAGAGGTTGTGCAGCTGAGA-3′) Syncytin, and β-actin (forward, 5′-CTTCTACAAT- GAGCTGGGTG-3′ and reverse, 5′-TCATGAGGTAGTCAGTCAGG-3′) mRNAs alone or together (multiplex), as previously described (10).
    Human Leukemia Inhibitory Factor Soluble Receptor α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+leukemia+inhibitory+factor+lif+antibodies/Human+LIF+Antibody/pm14513546-62-52-60
    Average 93 stars, based on 1 article reviews
    human leukemia inhibitory factor soluble receptor α - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Cytokines/growth factors released into the conditioned medium of hAFSCs and MSCs and effects on tubular cell proliferation. A: Evaluation of cytokines/growth factors released into the conditioned medium of 1 × 106 hAFSCs and MSCs after a 12-hour incubation in RPMI 1640 plus 0.5% bovine serum albumin. Cytokines were measured using a multiplex cytokine array. Data represent the mean ± SD of five different cell lines. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; LIF, leukemia inhibitory factor; NGF, nerve growth factor; SCF, stem cell factor; SDF, stromal derived factor; HGF, hepatocyte growth factor. B: Proliferation of TECs induced by the conditioned medium (CM) of hAFSCs and MSCs was evaluated by incorporation of BrdU and expressed as the percent increase over unstimulated control cells (Ctrl). The role of LIF in proliferation induced by the conditioned medium was evaluated using 3 μg/ml anti-LIF blocking antibodies (Ab-LIF). Data represent the mean ± SD of three different experiments performed in duplicate. Analysis of variance with Dunnett's comparison test: *P < 0.005, CM plus Ab-LIF versus CM alone.

    Journal: The American Journal of Pathology

    Article Title: Stem Cells Derived from Human Amniotic Fluid Contribute to Acute Kidney Injury Recovery

    doi: 10.2353/ajpath.2010.091245

    Figure Lengend Snippet: Cytokines/growth factors released into the conditioned medium of hAFSCs and MSCs and effects on tubular cell proliferation. A: Evaluation of cytokines/growth factors released into the conditioned medium of 1 × 106 hAFSCs and MSCs after a 12-hour incubation in RPMI 1640 plus 0.5% bovine serum albumin. Cytokines were measured using a multiplex cytokine array. Data represent the mean ± SD of five different cell lines. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; LIF, leukemia inhibitory factor; NGF, nerve growth factor; SCF, stem cell factor; SDF, stromal derived factor; HGF, hepatocyte growth factor. B: Proliferation of TECs induced by the conditioned medium (CM) of hAFSCs and MSCs was evaluated by incorporation of BrdU and expressed as the percent increase over unstimulated control cells (Ctrl). The role of LIF in proliferation induced by the conditioned medium was evaluated using 3 μg/ml anti-LIF blocking antibodies (Ab-LIF). Data represent the mean ± SD of three different experiments performed in duplicate. Analysis of variance with Dunnett's comparison test: *P < 0.005, CM plus Ab-LIF versus CM alone.

    Article Snippet: 29 The cells were seeded at 4000 cells/well into 96-well plates in Dulbecco's modified Eagle's medium (Sigma-Aldrich), deprived of fetal calf serum incubated with or without 3 μg/ml of human leukemia inhibitory factor (LIF) blocking antibody (R&D Systems) in the presence of 30% conditioned medium from hAFSCs or MSCs.

    Techniques: Incubation, Multiplex Assay, Derivative Assay, Control, Blocking Assay, Comparison

    Figure 1. Comparison of yield and immunoreactivity of proteins from chorionic villous samples extracted and solubilized with different reagents. (A) Glycogen, at a high pH, and sarkosyl (SK) increased the solubility of proteins in TRIZOL protein pellets from villous tissue (39-week pregnancy). Protein pellets, precipitated from TRIZOL supernatants in the absence of glycogen, were extracted with 50 mM Tris-Cl buffer at the pH indicated from the equivalent of 2.5 mg tis- sue (lanes 2–9), from 1–10 mg tissue precipitated in the presence of glycogen (lanes 11–14; in lane 11, 2.5 mg tissue equivalent were loaded and, in lane 12, 2 mg tissue equivalent were loaded), and from 2 mg tissue with or without sarkosyl at pH 6.8 (lanes 16 and 17) and at pH 8.8 (lanes 18 and 19). Protein concentrations from six different experiments were measured, and the mean (x– ± SEM) relative increase in recovery at pH 7.5, 8.0, and 8.8, compared to that at pH 6.8, are shown (lanes 2–9). Patient samples were villous tissues from two 39-week (39- and 38.4-week, caesarean delivery), two 12-week (12- and 12.1-week, voluntary termi- nation of pregnancy) pregnancies, and fetal brain (13.1-week with Down syndrome). (B) Lanes 2–5, proteins were directly extracted from 50 mg villous tissue (39-week pregnancy) at pH 8.0, tissue protein extraction reagent (T-PER), and from TRIZOL pellets (lanes 6 and 7). (C) Villous proteins (38.4-week pregnancy) extracted directly (lanes 1–4) at conditions indicated were resolved in 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels, electrotransferred to Immobilon polyvinylidene difluoride (PVDF) membrane, immunostained [upper panel; antibody (Ab)] with affinity-purified polyclonal goat anti-human interferon γ recep- tor (IFNGR) 2, and membranes were then stained with 0.25% Coomassie blue (lower panel; stain). (D) Similar experiment to panel A (lanes 2–9), except that vil- lous tissue was from a 12-week pregnancy and the proteins transferred to a PVDF membrane were first immunoreacted with anti-human IFNGR 2 antibody, and, subsequently, the membrane was stripped and reprobed with β-actin antibody. Fold increase in staining at different pHs compared to that at pH 6.8 is shown below the bands; lanes 9 and 10, proteins were extracted at pH 8.8, and fold-increase by glycogen is shown for IFNGR 2 and β-actin. (E) Similar experiment (villous tissue from a 12.1-week pregnancy) to panel D, except it was first immunostained with anti-human leukemia inhibitory factor-soluble receptor α (LIF-sRα) and subsequently with β-actin. (F) Villous proteins (38.4-week pregnancy) were extracted at pH 6.8 (lanes 1 and 2), pH 8.0 (lanes 3 and 4), and pH 8.8 (lanes 5 and 6) in the presence and absence of sarkosyl. (G) RNA analysis from samples used for protein extraction; lanes 1 and 2, 5 µg total RNA from experiments shown in panels A–C and F (two 39-week villous tissue) were resolved on agarose gel, which demonstrated the quality of 28S and 18S ribosomal RNAs; the cDNA pre- pared from 12-week (Figure 1D) and 39-week pregnancies (A) were used to amplify IFNGR1 (forward, 5′-GAATGAACGGAAGTGAGATCCA-3′ and reverse, 5′-CCTGGAACTGTTGCTGGAGA-3′), 8.0 (forward, 5′-TCAGGGATAGCCCCCATCTAT-3′ and reverse, 5′-AACCCTTTGCCACTACATCAATTT-3′), and 3.1 kb (forward, 5′-CCGCTGAAAGAGGGGGAA-3′ and reverse, 5′-TAGAGGTTGTGCAGCTGAGA-3′) Syncytin, and β-actin (forward, 5′-CTTCTACAAT- GAGCTGGGTG-3′ and reverse, 5′-TCATGAGGTAGTCAGTCAGG-3′) mRNAs alone or together (multiplex), as previously described (10).

    Journal: BioTechniques

    Article Title: Quantitative recovery of immunoreactive proteins from clinical samples following RNA and DNA isolation.

    doi: 10.2144/03353bm02

    Figure Lengend Snippet: Figure 1. Comparison of yield and immunoreactivity of proteins from chorionic villous samples extracted and solubilized with different reagents. (A) Glycogen, at a high pH, and sarkosyl (SK) increased the solubility of proteins in TRIZOL protein pellets from villous tissue (39-week pregnancy). Protein pellets, precipitated from TRIZOL supernatants in the absence of glycogen, were extracted with 50 mM Tris-Cl buffer at the pH indicated from the equivalent of 2.5 mg tis- sue (lanes 2–9), from 1–10 mg tissue precipitated in the presence of glycogen (lanes 11–14; in lane 11, 2.5 mg tissue equivalent were loaded and, in lane 12, 2 mg tissue equivalent were loaded), and from 2 mg tissue with or without sarkosyl at pH 6.8 (lanes 16 and 17) and at pH 8.8 (lanes 18 and 19). Protein concentrations from six different experiments were measured, and the mean (x– ± SEM) relative increase in recovery at pH 7.5, 8.0, and 8.8, compared to that at pH 6.8, are shown (lanes 2–9). Patient samples were villous tissues from two 39-week (39- and 38.4-week, caesarean delivery), two 12-week (12- and 12.1-week, voluntary termi- nation of pregnancy) pregnancies, and fetal brain (13.1-week with Down syndrome). (B) Lanes 2–5, proteins were directly extracted from 50 mg villous tissue (39-week pregnancy) at pH 8.0, tissue protein extraction reagent (T-PER), and from TRIZOL pellets (lanes 6 and 7). (C) Villous proteins (38.4-week pregnancy) extracted directly (lanes 1–4) at conditions indicated were resolved in 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels, electrotransferred to Immobilon polyvinylidene difluoride (PVDF) membrane, immunostained [upper panel; antibody (Ab)] with affinity-purified polyclonal goat anti-human interferon γ recep- tor (IFNGR) 2, and membranes were then stained with 0.25% Coomassie blue (lower panel; stain). (D) Similar experiment to panel A (lanes 2–9), except that vil- lous tissue was from a 12-week pregnancy and the proteins transferred to a PVDF membrane were first immunoreacted with anti-human IFNGR 2 antibody, and, subsequently, the membrane was stripped and reprobed with β-actin antibody. Fold increase in staining at different pHs compared to that at pH 6.8 is shown below the bands; lanes 9 and 10, proteins were extracted at pH 8.8, and fold-increase by glycogen is shown for IFNGR 2 and β-actin. (E) Similar experiment (villous tissue from a 12.1-week pregnancy) to panel D, except it was first immunostained with anti-human leukemia inhibitory factor-soluble receptor α (LIF-sRα) and subsequently with β-actin. (F) Villous proteins (38.4-week pregnancy) were extracted at pH 6.8 (lanes 1 and 2), pH 8.0 (lanes 3 and 4), and pH 8.8 (lanes 5 and 6) in the presence and absence of sarkosyl. (G) RNA analysis from samples used for protein extraction; lanes 1 and 2, 5 µg total RNA from experiments shown in panels A–C and F (two 39-week villous tissue) were resolved on agarose gel, which demonstrated the quality of 28S and 18S ribosomal RNAs; the cDNA pre- pared from 12-week (Figure 1D) and 39-week pregnancies (A) were used to amplify IFNGR1 (forward, 5′-GAATGAACGGAAGTGAGATCCA-3′ and reverse, 5′-CCTGGAACTGTTGCTGGAGA-3′), 8.0 (forward, 5′-TCAGGGATAGCCCCCATCTAT-3′ and reverse, 5′-AACCCTTTGCCACTACATCAATTT-3′), and 3.1 kb (forward, 5′-CCGCTGAAAGAGGGGGAA-3′ and reverse, 5′-TAGAGGTTGTGCAGCTGAGA-3′) Syncytin, and β-actin (forward, 5′-CTTCTACAAT- GAGCTGGGTG-3′ and reverse, 5′-TCATGAGGTAGTCAGTCAGG-3′) mRNAs alone or together (multiplex), as previously described (10).

    Article Snippet: The effects of pH, glycogen, and sarkosyl on the retrieval of proteins from TRIZOL pellets were verified (Figure 1, C–F) by the Western transfer of proteins to ImmobilonTM polyvinylidene difluoride (PVDF) membranes (Millipore, Watford, UK), followed by detection using antibodies raised against various epitopes [human interferon γ receptors (IFNGR) 1 and 2; human leukemia inhibitory factor-soluble receptor α (LIF sRα) (R&D Systems, Oxford, UK); β-actin, clone AC-15 (Sigma, Poole, Dorset, UK)].

    Techniques: Comparison, Solubility, Protein Extraction, Membrane, Affinity Purification, Staining, Agarose Gel Electrophoresis, Multiplex Assay